Neoplasms, Breast
Conditions
Keywords
lapatinib, Metastatic ErbB2 positive breast cancer, digoxin
Brief summary
This is a two part study looking at the effect of lapatinib on concentrations of digoxin in the blood when both drugs are dosed together in Part 1; and looking at the safety and antitumor effect of lapatinib when used together with possible additional anticancer therapy as chosen at the doctor's discretion.
Interventions
DRUGlapatinib
1500 mg oral lapatinib starting Day 2 continuing through Day 9. Part 2 subjects received 1500mg daily through week 10.
DRUGDigoxin
0.5mg on Days 1 and 9
Sponsors
GlaxoSmithKline
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Metastatic, histologically confirmed breast cancer that overexpresses ErbB2 (3+ by IHC, FISH, or CISH positive). * Is at least 18 years of age and not greater than 65 years of age. * Is male or female. * A female is eligible to enter and participate in the study if she is of: \- Non-childbearing potential (i.e. physiologically incapable of becoming pregnant), including any female who: * Has had a hysterectomy * Has had a bilateral oophorectomy (ovariectomy) * Has had a bilateral tubal ligation, or * Is post-menopausal (a demonstration of total cessation of menses for ≥ 1 year) or \- Childbearing potential, has a negative serum pregnancy test at Screening and agrees to one of the following: * Double-barrier contraception (condom with spermicidal jelly, foam, suppository, or film; diaphragm with spermicide; or male condom and diaphragm). * Complete abstinence from sexual intercourse from two weeks prior to administration of the study drug, throughout the active study treatment period, and through the Week 10 Visit. * Vasectomized partner who is sterile prior to the female subject's entry and is the sole sexual partner for that female. * Is able to swallow and retain oral medication. * ECOG performance status 0 to 2. * Provided written informed consent. * Adequate bone marrow function. * Clinical lab results with ranges as stated per protocol. * Potassium and magnesium within the normal range of institutional values. \[Serum potassium or magnesium values that fall outside the normal range may be repeated once at the discretion of the investigator, provided they are considered to be clinically insignificant.\] * Has a left ventricular ejection fraction (LVEF) within the normal institutional range based on ECHO or MUGA. * Life expectancy of at least 12 weeks * Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
Exclusion criteria
* Is pregnant or lactating. * Has malabsorption syndrome, a disease affecting gastrointestinal function, or resection of the stomach or small bowel. * Has evidence of symptomatic or uncontrolled brain metastases or leptomeningeal disease. Subjects with brain metastases treated by surgery and/or radiotherapy are eligible if neurologically stable and do not require steroids or anticonvulsants. * Is considered medically unfit for the study by the investigator as a result of the medical interview, physical exam, or screening investigations. * Has CTCAE Grade 2 or greater hypercalcemia as per protocol. * Has a known immediate or delayed hypersensitivity reaction or idiosyncrasy to digoxin or drugs chemically related to the investigational product such as gefitinib \[Iressa\] and erlotinib \[Tarceva\]. * Has received treatment with any investigational drug in the previous four weeks. * Has received chemotherapy, immunotherapy, biologic therapy or hormonal therapy for the treatment of cancer within the past 14 days, with the exception of mitomycin C which is restricted for the past six weeks. * Is currently receiving amiodarone or has received amiodarone in the six months prior to screening. * Is receiving any prohibited medication within the timeframe indicated on the prohibited medication list as per protocol. * Has physiological, familial, sociological, or geographical conditions that do not permit compliance with the protocol. * Subjects with certain disorders involving heart failure associated with preserved left ventricular ejection fraction such as restrictive cardiomyopathy, constrictive pericarditis, amyloid heart disease, acute cor pulmonale, idiopathic hypertrophic subaortic stenosis, or any other cardiac condition that would preclude the administration of digoxin. * Has a clinically significant electrocardiogram (ECG) abnormality, including but not limited to sinus node disease, pre-existing incomplete AV block, and Wolff Parkinson-White Syndrome. * Has inadequate venous access for protocol-related blood draws.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To characterize the effect of repeat oral dose lapatinib treatment on the pharmacokinetics of a single oral dose of digoxin in adult subjects with metastatic ErbB2 positive breast cancer. | 10 days |
Secondary
| Measure | Time frame |
|---|---|
| Safety and tolerability assessments including evaluation of adverse events (AEs) and changes in laboratory values, and vital signs. | 10 days |
Countries
Canada, South Korea, United States
Outcome results
None listed